MIT Center for Biomedical Innovation

Biopharmaceutical Research and Biomanufacturing Servicescbi.mit.edu

Company typePrivate
Founded2005
HeadquartersCambridge, United States
Headcount5,001–10,000
GTM typeB2B
OfferingServices

MIT Center for Biomedical Innovation firmographics

Firmographics

Name: MIT Center for Biomedical Innovation
Legal name: MIT Center for Biomedical Innovation
Website: https://cbi.mit.edu
Company type: Private
Founded year: 2005
Operating status: Operating
Headcount range: 5,001–10,000 employees
Ownership category
akta.pro rank

MIT Center for Biomedical Innovation industry classification

Industry

Product category: Biopharmaceutical Research and Biomanufacturing Services
NAICS: Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC: Services-Commercial Physical & Biological Research (8731)
akta.pro primary industry: Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI)
akta.pro secondary industries: Health, Pharmaceuticals & Medical Devices Regulatory Cooperation (BPADANAJ), STEM-Focused Research Universities (Engineering & Applied Sciences) (EDAHABAB)

Keywords

Biomanufacturing research
Biologics manufacturing
Pharmaceutical consortium services
Continuous manufacturing platforms
Bioprocess education programs

Where MIT Center for Biomedical Innovation is headquartered

Location

Headquarters

HQ city: Cambridge
HQ country: United States
HQ region: North America

Offices1 record

Markets served

MIT Center for Biomedical Innovation business model

Business model

GTM type: B2B
Offering type: Services
Cost components: Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Others

Revenue model

Consortium Membership Fees: Pre-competitive industry consortia (BioMAN, CAACB) where member companies pay fees to participate in collaborative research, benchmarking, networking, and industry consensus development
Government Research Grants: Funding from agencies including FDA ($82M for continuous mRNA manufacturing), ARPA-H (multiple funded projects), and NIIMBL for specific biomanufacturing research projects
ARPA-H Funded Contracts: Participates in ARPA-H funded contracts for OCULAB biomarker detection and extracellular vesicle manufacturing platform development

Pricing tiers

Model	Billing	Price
Unit Pricing	Multi-year contract	Vaccines Bioprocess Development Workshop - Industry
Unit Pricing	Multi-year contract	Vaccines Bioprocess Development Workshop - Government/NGO/Non-Profit
Unit Pricing	Multi-year contract	Vaccines Bioprocess Development Workshop - MIT Affiliate

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

MIT Center for Biomedical Innovation product offering

Product offering

Core offering

MIT Center for Biomedical Innovation is an academic research center that runs pre-competitive industry consortia (BioMAN and CAACB), executes applied research projects, and delivers biomanufacturing-focused educational courses for pharmaceutical, biotech, and government stakeholders. It focuses on biomanufacturing process innovation for biologic medicines including monoclonal antibodies, vaccines, viral vectors, and cell therapies, and operates as a neutral collaboration engine convening industry, academia, and government.

Product overview

MIT Center for Biomedical Innovation (CBI) is a collaboration engine that provides integrated solutions to global health challenges. The organization operates several named consortium programs including BioMAN (Biomanufacturing Consortium) focused on manufacturing challenges for biologics, and CAACB (Consortium on Adventitious Agent Contamination in Biomanufacturing) focused on viral safety. CBI also manages research initiatives including SMART CAMP for personalized medicine manufacturing analytics, the FoCUS Project for financing novel medicines, and the BioACCESS global health initiative. The organization offers educational programs including residential and online courses on protein/antibody drug manufacturing, cell therapy training, and vaccine bioprocess courses with University College London. Research activities focus on biomanufacturing process innovation including process analytical technologies, data analytics, advanced process modeling, and continuous manufacturing for biologics including monoclonal antibodies, vaccines, viral vectors, and cell therapies.

Differentiator

Problem solved

Functional benefit

Brands

BioMAN: Biomanufacturing Consortium - pre-competitive program providing safe haven where industry, academia, and government collaboratively address challenges in manufacturing, delivery, and access of biologics
CAACB
BioACCESS
NEWDIGS

Products and services

BioMAN Biomanufacturing Consortium Pre-competitive consortium for industry, academia, and government to collaboratively address manufacturing, delivery, and access challenges for biologic medicines through focused events and projects.
CAACB Consortium on Adventitious Agent Contamination in Biomanufacturing Consortium pooling biopharmaceutical manufacturing expertise to enable safe and reliable delivery of life-saving biologics through collaborative projects, benchmarking, and industry consensus on viral safety.
Cell Therapy Manufacturing Training Program Blended learning course combining online learning with hands-on training for cell therapy manufacturing personnel, developed by MIT CBI for training manufacturing staff.
Online Course on Protein and Antibody Drug Manufacturing Online course on the principles of manufacturing protein and antibody drugs, part of MIT CBI's biomanufacturing educational offerings.
Vaccines Bioprocess Development and Commercialisation Course (with UCL) Short course on vaccine bioprocess development and commercialisation offered jointly by MIT CBI and University College London for industry and academic participants.
SMART CAMP (Critical Analytics for Manufacturing Personalized-Medicine) Interdisciplinary research program developing critical analytics and smart manufacturing tools that support a risk-based framework for personalized cell-medicine manufacturing.
Biomanufacturing Process Innovation Research Research projects on biomanufacturing process innovation for production of biologic medicines including monoclonal antibodies, vaccines, viral vectors, and cell therapies, spanning process analytical technologies, biomanufacturing data analytics, advanced process modeling and control, and continuous manufacturing.

Quantifiable outcome

$82M FDA award for continuous mRNA manufacturing development
+2 more outcomes

Companies that use MIT Center for Biomedical Innovation

Customer profile

Named customers12 records

Segments3 records

Ideal customer profiles3 records

MIT Center for Biomedical Innovation technology and API

Technology

Technology focussed Yes

API detail

Has API: No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature9 records

MIT Center for Biomedical Innovation partnerships and signals

Strategic signal

Partnerships

27 partnerships are on record, tiered core, member, project partner, research partner and education partner.

Singapore-MIT Alliance for Research and Technology (SMART)coreStrategic or Co-development Partner · 15 July 2019CBI collaborating on Critical Analytics for Manufacturing Personalized-Medicine (CAMP) flagship research project, supported by Singapore National Research Foundation, involving leading universities and hospitals in Singapore
AllogenememberStrategic or Co-development PartnerBioMAN consortium member - a clinical-stage biotechnology company developing allogeneic CAR T cell therapies
SartoriusmemberStrategic or Co-development PartnerBioMAN consortium member - a supplier for bioprocessing equipment and services
CSL BehringmemberStrategic or Co-development PartnerBioMAN consortium member - a global biotechnology company developing medicines for rare diseases
TakedamemberStrategic or Co-development PartnerBioMAN consortium member - a global pharmaceutical company with biomanufacturing operations
Boehringer IngelheimmemberStrategic or Co-development PartnerBioMAN consortium member - a research-driven pharmaceutical company
GenentechmemberStrategic or Co-development PartnerBioMAN consortium member - a biotechnology pioneer and member of Roche group
PfizermemberStrategic or Co-development PartnerBioMAN consortium member - a global pharmaceutical company engaged in biomanufacturing
GSKmemberStrategic or Co-development PartnerBioMAN consortium member and workshop speaker - a global healthcare company
SanofimemberStrategic or Co-development PartnerBioMAN consortium member - a global pharmaceutical company focused on immunology and vaccines
AstraZenecamemberStrategic or Co-development PartnerBioMAN consortium member - a global biopharmaceutical company
Bristol Myers SquibbmemberStrategic or Co-development PartnerBioMAN consortium member - a global biopharmaceutical company
MerckmemberStrategic or Co-development PartnerBioMAN consortium member - operating as EMD Serono/MilliporeSigma in the US
AmgenmemberStrategic or Co-development PartnerBioMAN consortium member - a biotechnology company focused on human therapeutics
Thermo Fisher ScientificmemberStrategic or Co-development PartnerBioMAN consortium member - a supplier of scientific instrumentation and bioprocessing solutions
BiogenmemberStrategic or Co-development PartnerBioMAN consortium member - a biotechnology company focused on neurological diseases
Eli LillymemberStrategic or Co-development PartnerBioMAN consortium member - a global pharmaceutical company
Charles River LaboratoriesmemberStrategic or Co-development PartnerBioMAN consortium member - a non-clinical drug development company
CytivamemberStrategic or Co-development PartnerBioMAN consortium member - a global provider of technologies and services for biomanufacturing
Landmark Bioproject partnerStrategic or Co-development PartnerNIIMBL project participant and subaward recipient for ARPA-H extracellular vesicle manufacturing platform project
EMD Millipore Corporationproject partnerStrategic or Co-development PartnerNIIMBL project participant for upstream enrichment and AAV capsid scale-up project
Virica Biotechproject partnerStrategic or Co-development PartnerNIIMBL project participant for upstream enrichment and AAV capsid scale-up project
A*STAR Skin Research Labsresearch partnerStrategic or Co-development PartnerCollaborating with SMART CAMP researchers on rapid microbial contamination detection using elastic light scatter phenotyping
National University of Singaporeresearch partnerStrategic or Co-development PartnerCollaborating with SMART CAMP researchers on rapid microbial contamination detection method
University College Londoneducation partnerStrategic or Co-development PartnerJoint educational offerings including short course on vaccine manufacturing and Vaccines Bioprocess Development and Commercialisation course
MIT Sloan School of ManagementcoreStrategic or Co-development PartnerCBI draws on expertise from MIT's Schools of Engineering, Science, and Sloan School of Management
Oxford Nanopore TechnologiesmemberStrategic or Co-development PartnerBioMAN consortium member - provider of nanopore sequencing technology

Scale indicators4 records

Recent moves7 records

Expansion highlights3 records

MIT Center for Biomedical Innovation competitors and assessment

Company assessment

Others

BPI (BioProcess International): Industry media and events brand covering bioprocess development and manufacturing. Adjacent ecosystem participant to MIT CBI's BioMAN Summits and CAACB Workshops, facilitating similar industry knowledge-sharing and networking.

Direct peers

Golden LEAF Biomanufacturing Training and Education Center (NC State BTEC): NIIMBL-affiliated academic bioprocess training and education facility offering hands-on training and pilot-scale biomanufacturing. Comparable to MIT CBI on the biomanufacturing workforce-development and process-research mandate.
BioPhorum: Global pre-competitive biopharmaceutical industry consortium running member-driven workstreams across biomanufacturing, supply chain, and quality. Directly comparable to MIT CBI's BioMAN/CAACB model of bringing members together to address shared manufacturing challenges.
National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL): US public-private Manufacturing Innovation Institute focused on biopharmaceutical manufacturing innovation and workforce development. Closest direct peer to MIT CBI as a federally-backed academic-led biomanufacturing collaboration platform with overlapping industry membership.
Tufts Center for the Study of Drug Development (CSDD): Academic research center running cross-stakeholder programs on drug development innovation, including the recently relocated NEWDIGS initiative formerly hosted at MIT CBI. Closely mirrors CBI's pre-competitive collaboration engine structure.
CASSS (California Separation Science Society): Non-profit scientific organization that runs pre-competitive consortia-like symposia (e.g., WCBP) and share groups for bioanalytical, CMC, and bioprocess characterization—closely aligned with CBI's CAACB and BioMAN operating model of neutral-venue industry consensus work.
Georgia Tech Institute for Bioengineering and Bioscience (IBB): Interdisciplinary academic bioengineering center at a private research university, running industry-funded translational research and training programs. Comparable to MIT CBI in combining industry consortia, training, and process/bioprocess research.

Broad incumbents

Lonza Biologics: Global CDMO providing mammalian and microbial biologics, viral vector, and cell therapy manufacturing services. Indirect incumbent in CBI's biomanufacturing domain and a likely industry participant in CBI-adjacent consortia.
Catalent: Large commercial CDMO providing biologics, cell therapy, and gene therapy manufacturing services at scale. A BioMAN member and broader incumbent in the same biomanufacturing space MIT CBI researches, though operating on a contract-services rather than collaborative-consortium model.
NCATS (NIH National Center for Advancing Translational Sciences): Federal translational-science institute funding collaborative R&D across academia, industry, and government, including innovative manufacturing platforms. Comparable to CBI in bridging research and clinical/manufacturing translation but operating across the full translational spectrum rather than biomanufacturing-only.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

MIT Center for Biomedical Innovation financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MIT Center for Biomedical Innovation leadership team

Management profile

Number of profiles

Profiles2 records

MIT Center for Biomedical Innovation subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

MIT Center for Biomedical Innovation funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MIT Center for Biomedical Innovation M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MIT Center for Biomedical Innovation

What does MIT Center for Biomedical Innovation do?

Is MIT Center for Biomedical Innovation a public or private company?

MIT Center for Biomedical Innovation is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was MIT Center for Biomedical Innovation founded?

MIT Center for Biomedical Innovation was founded in 2005. It employs 5,001 to 10,000 people.

Where is MIT Center for Biomedical Innovation based?

MIT Center for Biomedical Innovation is headquartered in Cambridge, United States, in the North America region.

How does MIT Center for Biomedical Innovation make money?

Three revenue lines are on record. Consortium Membership Fees are the primary driver. The others are government Research Grants and ARPA-H Funded Contracts.

Who are MIT Center for Biomedical Innovation's main competitors?

BPI (BioProcess International) is listed as an others. Direct peers are Golden LEAF Biomanufacturing Training and Education Center (NC State BTEC), BioPhorum, National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), Tufts Center for the Study of Drug Development (CSDD), CASSS (California Separation Science Society) and Georgia Tech Institute for Bioengineering and Bioscience (IBB). Broad incumbents are Lonza Biologics, Catalent and NCATS (NIH National Center for Advancing Translational Sciences).

Does MIT Center for Biomedical Innovation have an API?

No public API is recorded for MIT Center for Biomedical Innovation.

What industry is MIT Center for Biomedical Innovation in?

MIT Center for Biomedical Innovation's product category is Biopharmaceutical Research and Biomanufacturing Services. Its primary akta.pro industry code is EDAHAGAI, Biomedical Sciences & Medical Research Institutes (University-Based), with a secondary code of BPADANAJ, Health, Pharmaceuticals & Medical Devices Regulatory Cooperation. Its NAICS code is 54171 and its SIC code is 8731.